Host Hamza Shah, OD, MS, FAAO, is joined by Andrew Rixon, OD, FAAO, to discuss OCT and OCTA's utility in identifying neurogeneration, inspired by Lepoittevin et al's paper, "Retinal biomarkers for early Alzheimer's detection: a systematic review of optical coherence tomography (OCT) findings."
Weighing in on The Lancet Diabetes & Endocrinology's expert panel and its division of obesity diagnoses.
Catch up on the top stories in optometry during the week of July 27-31.
PROSE treatment and Mackie stage improvement in neurotrophic keratitis: retrospective study design and primary results.
Maria Sampalis, OD, weighs in on how she has tripled her private practice's growth during her career and how she has used the back to school season as an opportunity to strengthen that growth.
Philip Morgan, BSc, PhD, MCOptom, FAAO, and Lyndon Jones, DSc, PhD, FCOptom, discuss the latest data on contact lens profitability released from the Contact Lens Institute.
Toric, spheric, and multifocal contact lenses are 86%, 79%, and 29% more profitable, respectively, than equivalent glasses-only patients.
Glaukos finishes US pivotal enrollment for Preserflo MicroShunt, targeting advanced glaucoma after failed surgeries, with 12‑month IOP reduction data guiding FDA plans.
The trial will enroll approximately 111 patients across the US and Europe following positive FDA feedback from a Type D meeting
Jade Coats, OD, FAAO, stated that providing pre- and post-op patient care can provide an opportunity to support ophthalmologists.
Through at home delivery, and in-office dispense in permitted states, Orasis Pharmaceuticals and BlinkRx aim to improve accessibility of Qlosi eye drops for presbyopia treatment.
Protecting eye health today requires more than regular eye exams and good lighting
The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the US.
Michael Ip, MD, presented a large-scale analysis of OCT biomarkers in diabetic macular edema (DME), drawing on data from the DRCR Retina Network's Protocol T trial.
The FDA confirmed phase 1 and nonclinical data support pediatric phase 2 development of IVMED-85, a non-atropine daily eye drop for myopia progression.
Bausch + Lomb’s EyeGility preloaded enVista IOL inserter streamlines cataract surgery with push-plunger delivery, less handling, and faster workflow.
Frantz EyeCare reported 98% of Light Adjustable Lens patients within ±0.50 D of target but omitted cohort, follow-up, and safety details.
i-Lumen Scientific randomly assigned its first US patient in the sham-controlled i-SIGHT2 pivotal study of its investigational, noninvasive bioelectric AMD device at Texas Retina Associates.
A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.
Jessica Steen, OD, FAAO, DipABO, stated that each ADC can have distinct ophthalmic monitoring needs and management protocols.
Lab-grown retinal endothelial cells from iPSCs rebuild mouse retinal vessels and power blood-retina barrier chips, accelerating diabetic retinopathy research and therapy discovery.
A disconnect between the signs and symptoms of OSD can easily lead to misdiagnosis or undertreatment if clinicians rely solely on a slit lamp observation.
University of Waterloo unveils chairside 3D-printed contacts, delivering custom-fit lenses in 20 minutes—potentially cutting weeks of trial fittings for irregular corneas.
NEI-funded US trial compares HALT MAX lenses, 0.05% atropine, and combination therapy to slow childhood myopia and axial elongation.
Esen K. Akpek, MD, speaks with the Eye Care Network in recognition of Dry Eye Awareness Month.
A new pilot trial tests ZOC2017217 lanosterol-derived cataract eye drops, aiming to slow lens clouding and guide Phase 3 development amid mixed human evidence.
In this Q&A, LENZ CFO Dan Chevallard on Vizz's ECP momentum, telehealth expansion, and the global push to end reading glasses for presbyopia.
Antineoplastics were the most frequently implicated drug class in review
The company said it will now focus solely on developing what it describes as the first small-molecule sustained-release implant for geographic atrophy, with clinical trials expected to begin in 2028.
Neda Gioia, OD, CNS, FMCP, FOWNS, CFMP, stated that preparing optometric students for the possibility of burnout may help reduce its prevalence.
